Synonyms: AC-5216 | XBD-173 | XBD173
Compound class:
Synthetic organic
Comment: Emapunil (XBD173) is an orally bioavailable translocator protein (TSPO) phenylpurine ligand. TSPO was originally identified as a molecular target for the development of new anxiolytic drugs [1-2,5]. More recently, TSPO is being pursued as a novel neuroimmunodulatory target for disease-modifying benefit in secondary progressive MS (SPMS), based on preclinical evidence of immunomodulatory effects on monocytes/macrophages and microglia that appear to induce a reparative phenotype in these immune cell types [3-4].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Emapunil (XBD173) is being evaluated for neuroimmunodulatory potential. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03850301 | Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target | N/A Interventional | Imperial College London |